MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

A

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

Search

CareDx Inc

Abierto

SectorSanidad

20.17 0.35

Resumen

Variación precio

24h

Actual

Mínimo

19.88

Máximo

20.63

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.477

87.826

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+27.76% upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

268M

1.1B

Apertura anterior

19.82

Cierre anterior

20.17

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

155 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ene 2026, 23:54 UTC

Charlas de Mercado

CBA Could Underperform Again in 2026 -- Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

12 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ene 2026, 23:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ene 2026, 21:56 UTC

Charlas de Mercado

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ene 2026, 20:54 UTC

Ganancias

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ene 2026, 20:48 UTC

Charlas de Mercado

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ene 2026, 20:33 UTC

Charlas de Mercado

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ene 2026, 19:39 UTC

Charlas de Mercado

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 19:33 UTC

Charlas de Mercado

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ene 2026, 19:24 UTC

Adquisiciones, fusiones, absorciones

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ene 2026, 19:22 UTC

Adquisiciones, fusiones, absorciones

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ene 2026, 18:21 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ene 2026, 18:20 UTC

Adquisiciones, fusiones, absorciones

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ene 2026, 18:19 UTC

Charlas de Mercado

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ene 2026, 18:16 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ene 2026, 18:01 UTC

Adquisiciones, fusiones, absorciones

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ene 2026, 18:00 UTC

Charlas de Mercado

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

27.76% repunte

Estimación a 12 Meses

Media 22 USD  27.76%

Máximo 26 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

0

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

155 / 370 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat